Recent advances in plasmepsin medicinal chemistry and implications for future antimalarial drug discovery efforts

Current Topics in Medicinal Chemistry

Volumn 12, Issue 5, 2012, Pages 445-455

  Meyers, Marvin J ^a   Goldberg, Daniel E ^b  

^a SAINT LOUIS UNIVERSITY   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antimalarial; Aspartic protease inhibitor; Drug discovery; Medicinal chemistry; Plasmepsin

Indexed keywords

ACT 056822; ANTIMALARIAL AGENT; ASPARTIC PROTEINASE; HALOFANTRINE; HEMOGLOBIN; KNI 10006; KNI 10124; KNI 10125; KNI 10283; KNI 10743; PEPSTATIN; PEPTIDOMIMETIC AGENT; PLASMEPSIN; PLASMEPSIN 3; PLASMEPSIN 4; PLASMEPSIN 5; PLASMEPSIN 6; PLASMEPSIN 7; PLASMEPSIN 8; PLASMEPSIN I; PLASMEPSIN II; PLASMEPSIN INHIBITOR; PROTOZOAL PROTEIN; UNCLASSIFIED DRUG;

ANTIMALARIAL ACTIVITY; APICOMPLEXAN LIFE CYCLE STAGE; CELL VACUOLE; CRYSTAL STRUCTURE; DRUG POTENCY; DRUG RESEARCH; DRUG TARGETING; EDITORIAL; ENZYME INHIBITION; ERYTHROCYTE; IC 50; NONHUMAN; PARASITE VIRULENCE; PLASMODIUM; PLASMODIUM BERGHEI INFECTION; PLASMODIUM FALCIPARUM; PROTEIN DEGRADATION;

ANTIMALARIALS; ASPARTIC ACID ENDOPEPTIDASES; DRUG DISCOVERY; HUMANS; PROTEASE INHIBITORS;

EID: 84857694426     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802612799362959     Document Type: Editorial

References (69)

1. World malaria report 2010; World Health Organization: 2010; p http://www.who.int/malaria/world_malaria_report_2010/en/index.html.
2. Hyde, J. E. Drug-resistant malaria. Trends Parasitol., 2005, 21 (11), 494-498.
3. A research agenda for malaria eradication: Drugs. PLoS Med 2011, 8 (1), e1000402.
4. Li, F.; Patra, K. P.; Yowell, C. A.; Dame, J. B.; Chin, K.; Vinetz, J. M. Apical surface expression of aspartic protease plasmepsin 4, a potential transmission-blocking target of the plasmodium ookinete. J. Biol. Chem., 2010, 285 (11), 8076-8083.
5. Dame, J. B.; Yowell, C. A.; Omara-Opyene, L.; Carlton, J. M.; Cooper, R. A.; Li, T. Plasmepsin 4, the food vacuole aspartic proteinase found in all plasmodium spp. Infecting man. Mol. Biochem. Parasitol., 2003, 130 (1), 1-12.
6. Banerjee, R.; Liu, J.; Beatty, W.; Pelosof, L.; Klemba, M.; Goldberg, D. E. Four plasmepsins are active in the plasmodium falciparum food vacuole, including a protease with an active-site histidine. Proc. Natl. Acad. Sci. USA, 2002, 99 (2), 990-995.
7. Klemba, M.; Goldberg, D. E. Characterization of plasmepsin v, a membrane-bound aspartic protease homolog in the endoplasmic reticulum of plasmodium falciparum. Mol. Biochem. Parasitol., 2005, 143(2), 183-191.
8. Shea, M.; Jakle, U.; Liu, Q.; Berry, C.; Joiner, K. A.; Soldati-Favre, D. A family of aspartic proteases and a novel, dynamic and cellcycle- dependent protease localization in the secretory pathway of toxoplasma gondii. Traffic, 2007, 8 (8), 1018-1034.
9. Coombs, G. H.; Goldberg, D. E.; Klemba, M.; Berry, C.; Kay, J.; Mottram, J. C. Aspartic proteases of plasmodium falciparum and other parasitic protozoa as drug targets. Trends Parasitol., 2001, 17(11), 532-537.
10. Istvan, E. S.; Goldberg, D. E. Distal substrate interactions enhance plasmepsin activity. J. Biol. Chem., 2005, 280 (8), 6890-6896.
11. Gluzman, I. Y.; Francis, S. E.; Oksman, A.; Smith, C. E.; Duffin K. L.; Goldberg, D. E. Order and specificity of the plasmodium falciparum hemoglobin degradation pathway. J. Clin. Invest., 1994, 93(4), 1602-1608.
12. Goldberg, D. E.; Slater, A. F.; Beavis, R.; Chait, B.; Cerami, A.; Henderson, G. B. Hemoglobin degradation in the human malaria pathogen plasmodium falciparum: A catabolic pathway initiated by a specific aspartic protease. J. Exp. Med., 1991, 173(4), 961-969.
13. Rosenthal, P. J. Cysteine proteases of malaria parasites. Int. J. Parasitol., 2004, 34 (13-14), 1489-1499.
14. Liu, J.; Gluzman, I. Y.; Drew, M. E.; Goldberg, D. E. The role of plasmodium falciparum food vacuole plasmepsins. J. Biol. Chem., 2005, 280 (2), 1432-1437.
15. Sijwali, P. S.; Rosenthal, P. J. Gene disruption confirms a critical role for the cysteine protease falcipain-2 in hemoglobin hydrolysis by plasmodium falciparum. Proc. Natl. Acad. Sci. USA, 2004, 101 (13), 4384-4389.
16. Sijwali, P. S.; Koo, J.; Singh, N.; Rosenthal, P. J. Gene disruptions demonstrate independent roles for the four falcipain cysteine proteases of plasmodium falciparum. Mol. Biochem. Parasitol., 2006, 150 (1), 96-106.
17. Bonilla, J. A.; Bonilla, T. D.; Yowell, C. A.; Fujioka, H.; Dame, J. B. Critical roles for the digestive vacuole plasmepsins of plasmodium falciparum in vacuolar function. Mol. Microbiol., 2007, 65 (1), 64-75.
18. Liu, J.; Istvan, E. S.; Gluzman, I. Y.; Gross, J.; Goldberg, D. E. Plasmodium falciparum ensures its amino acid supply with multiple acquisition pathways and redundant proteolytic enzyme systems. Proc. Natl. Acad. Sci. USA, 2006, 103 (23), 8840-8845.
19. Drew, M. E.; Banerjee, R.; Uffman, E. W.; Gilbertson, S.; Rosenthal, P. J.; Goldberg, D. E. Plasmodium food vacuole plasmepsins are activated by falcipains. J. Biol. Chem., 2008, 283 (19), 12870-12876.
20. Spaccapelo, R.; Janse, C. J.; Caterbi, S.; Franke-Fayard, B.; Bonilla, J. A.; Syphard, L. M.; Di Cristina, M.; Dottorini, T.; Savarino, A.; Cassone, A.; Bistoni, F.; Waters, A. P.; Dame, J. B.; Crisanti, A. Plasmepsin 4-deficient plasmodium berghei are virulence attenuated and induce protective immunity against experimental malaria. Am. J. Pathol., 2010, 176(1), 205-217.
21. Bhaumik, P.; Gustchina, A.; Wlodawer, A. Structural studies of vacuolar plasmepsins. Biochim Biophys Acta 2011, 1824(1),207-223
22. Silva, A. M.; Cachau, R. E.; Sham, H. L.; Erickson, J. W. Inhibition and catalytic mechanism of hiv-1 aspartic protease. J. Mol. Biol., 1996, 255(2), 321-346.
23. Eder, J.; Hommel, U.; Cumin, F.; Martoglio, B.; Gerhartz, B. Aspartic proteases in drug discovery. Curr. Pharm. Des., 2007, 13(3), 271-285.
24. Berry, C.; Humphreys, M. J.; Matharu, P.; Granger, R.; Horrocks, P.; Moon, R. P.; Certa, U.; Ridley, R. G.; Bur, D.; Kay, J. A distinct member of the aspartic proteinase gene family from the human malaria parasite plasmodium falciparum. FEBS Lett., 1999, 447 (2-3), 149-154.
25. Xiao, H.; Sinkovits, A. F.; Bryksa, B. C.; Ogawa, M.; Yada, R. Y. Recombinant expression and partial characterization of an active soluble histo-aspartic protease from plasmodium falciparum. Protein Exp. Purif., 2006, 49 (1), 88-94.
26. Parr, C. L.; Tanaka, T.; Xiao, H.; Yada, R. Y. The catalytic significance of the proposed active site residues in plasmodium falciparum histoaspartic protease. Febs J., 2008, 275 (8), 1698-1707.
27. Bhaumik, P.; Xiao, H.; Parr, C. L.; Kiso, Y.; Gustchina, A.; Yada, R. Y.; Wlodawer, A. Crystal structures of the histo-aspartic protease (hap) from plasmodium falciparum. J. Mol. Biol., 2009, 388 (3), 520-540.
28. Maier, A. G.; Cooke, B. M.; Cowman, A. F.; Tilley, L. Malaria parasite proteins that remodel the host erythrocyte. Nat. Rev. Microbiol., 2009, 7(5), 341-354.
29. Marti, M.; Good, R. T.; Rug, M.; Knuepfer, E.; Cowman, A. F. Targeting malaria virulence and remodeling proteins to the host erythrocyte. Science, 2004, 306 (5703), 1930-1933.
30. Hiller, N. L.; Bhattacharjee, S.; van Ooij, C.; Liolios, K.; Harrison, T.; Lopez-Estrano, C.; Haldar, K. A host-targeting signal in virulence proteins reveals a secretome in malarial infection. Science, 2004, 306 (5703), 1934-1937.
31. Russo, I.; Babbitt, S.; Muralidharan, V.; Butler, T.; Oksman, A.; Goldberg, D. E. Plasmepsin v licenses plasmodium proteins for export into the host erythrocyte. Nature, 2010, 463 (7281), 632-636.
32. Boddey, J. A.; Hodder, A. N.; Günther, S.; Gilson, P. R.; Patsiouras, H.; Kapp, E. A.; Pearce, J. A.; de Koning-Ward, T. F.; Simpson, R. J.; Crabb, B. S.; Cowman, A. F. An aspartyl protease directs malaria effector proteins to the host cell. Nature, 2010, 463 (7281), 627-631.
33. Guruprasad, L.; Tanneeru, K.; Guruprasad, K. Structural rationale for the recognition of arginine at p(3) in pexel motif containing proteins of plasmodium falciparum by plasmepsin v. Protein Pept. Lett., 2011, 18 (6), 634-641.
34. Ghosh, A. K. Aspartic acid proteases as therapeutic targets. WILEY-VCH Verlag GmbH & Co. KGaA: Weinheim, Germany, 2010.
35. Gil, L. A.; Valiente, P. A.; Pascutti, P. G.; Pons, T. Computational perspectives into plasmepsins structure-function relationship: Implications to inhibitors design. J. Trop. Med., 2011, 2011 (2011), 657483.
36. Omara-Opyene, A. L.; Moura, P. A.; Sulsona, C. R.; Bonilla, J. A.; Yowell, C. A.; Fujioka, H.; Fidock, D. A.; Dame, J. B. Genetic disruption of the plasmodium falciparum digestive vacuole plasmepsins demonstrates their functional redundancy. J. Biol. Chem., 2004, 279 (52), 54088-54096.
37. New medicines for malaria control and eradication: Target product profiles for 2010. http://www.mmv.org/sites/default/files/uploads/docs/essential_info_for_scientists/Key_characteristics.pdf.
38. Boss, C.; Richard-Bildstein, S.; Weller, T.; Fischli, W.; Meyer, S.; Binkert, C. Inhibitors of the plasmodium falciparum parasite aspartic protease plasmepsin ii as potential antimalarial agents. Curr. Med. Chem., 2003, 10 (11), 883-907.
39. Bjelic, S.; Nervall, M.; Gutierrez-de-Teran, H.; Ersmark, K.; Hallberg, A.; Aqvist, J. Computational inhibitor design against malaria plasmepsins. Cell Mol. Life Sci., 2007, 64 (17), 2285-2305.
40. Ruben, A. J.; Kiso, Y.; Freire, E. The plasmepsin family as antimalarial drug targets. In: Aspartic Acid Proteases as Therapeutic Targets, Ghosh, A. K. Ed. WILEY-VCH Verlag GmbH & Co. KGaA: Weinheim, Germany, 2010; pp 513-547.
41. Gemma, S. Plasmepsin inhibitors as potential drugs against malaria: Starving the parasite. In: Aspartic Acid Proteases as Therapeutic Targets, Ghosh, A. K. Ed. WILEY-VCH Verlag GmbH & Co. KGaA: Weinheim, Germany, 2010; pp 549-571.
42. Ersmark, K.; Samuelsson, B.; Hallberg, A. Plasmepsins as potential targets for new antimalarial therapy. Med. Res. Rev., 2006, 26 (5), 626-666.
43. Bailly, E.; Jambou, R.; Savel, J.; Jaureguiberry, G. Plasmodium falciparum: Differential sensitivity in vitro to e-64 (cysteine protease inhibitor) and pepstatin a (aspartyl protease inhibitor). J. Protozool, 1992, 39 (5), 593-599.
44. Hidaka, K.; Kimura, T.; Ruben, A. J.; Uemura, T.; Kamiya, M.; Kiso, A.; Okamoto, T.; Tsuchiya, Y.; Hayashi, Y.; Freire, E.; Kiso, Y. Antimalarial activity enhancement in hydroxymethylcarbonyl (hmc) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin. Bioorg. Med. Chem., 2008, 16 (23), 10049-10060.
45. Miura, T.; Hidaka, K.; Uemura, T.; Kashimoto, K.; Hori, Y.; Kawasaki, Y.; Ruben, A. J.; Freire, E.; Kimura, T.; Kiso, Y. Improvement of both plasmepsin inhibitory activity and antimalarial activity by 2-aminoethylamino substitution. Bioorg. Med. Chem. Lett., 2010, 20 (16), 4836-4839.
46. Nezami, A.; Kimura, T.; Hidaka, K.; Kiso, A.; Liu, J.; Kiso, Y.; Goldberg, D. E.; Freire, E. High-affinity inhibition of a family of plasmodium falciparum proteases by a designed adaptive inhibitor. Biochemistry, 2003, 42 (28), 8459-8464.
47. Semenov, A.; Olson, J. E.; Rosenthal, P. J. Antimalarial synergy of cysteine and aspartic protease inhibitors. Antimicrob. Agents Chemother., 1998, 42 (9), 2254-2258.
48. Freire, E. In: Research Advances in Malaria. Resistance to Existing Drugs and New Drug Development, Tres Cantos, Spain, June 2-3; Tres Cantos, Spain, 2011.
49. Ahmed, W.; Rani, M.; Khan, I. A.; Iqbal, A.; Khan, K. M.; Haleem, M. A.; Azim, M. K. Characterisation of hydrazides and hydrazine derivatives as novel aspartic protease inhibitors. J. Enzyme Inhibit. Med. Chem., 2010, 25 (5), 673-678.
50. McKay, P. B.; Peters, M. B.; Carta, G.; Flood, C. T.; Dempsey, E.; Bell, A.; Berry, C.; Lloyd, D. G.; Fayne, D. Identification of plasmepsin inhibitors as selective anti-malarial agents using ligand based drug design. Bioorg. Med. Chem. Lett., 2011, 21 (11), 3335-3341.
51. Kasam, V.; Zimmermann, M.; Maab, A.; Schwichtenberg, H.; Wolf, A.; Jacq, N.; Breton, V.; Hofmann-Apitius, M. Design of new plasmepsin inhibitors: A virtual high throughput screening approach on the egee grid. J. Chem. Inf. Model., 2007, 47, 1818-1828.
52. Degliesposti, G.; Kasam, V.; Da Costa, A.; Kang, H. K.; Kim, N.; Kim, D. W.; Breton, V.; Kim, D.; Rastelli, G. Design and discovery of plasmepsin ii inhibitors using an automated workflow on largescale grids. ChemMedChem, 2009, 4 (7), 1164-1173.
53. Friedman, R.; Caflisch, A. Discovery of plasmepsin inhibitors by fragment-based docking and consensus scoring. ChemMedChem, 2009, 4 (8), 1317-1326.
54. Mendoza, A.; Perez-Silanes, S.; Quiliano, M.; Pabon, A.; Galiano, S.; Gonzalez, G.; Garavito, G.; Zimic, M.; Vaisberg, A.; Aldana, I.; Monge, A.; Deharo, E. Aryl piperazine and pyrrolidine as antimalarial agents. Synthesis and investigation of structureactivity relationships. Exp. Parasitol., 2011, 128 (2), 97-103.
55. Luksch, T.; Blum, A.; Klee, N.; Diederich, W. E.; Sotriffer, C. A.; Klebe, G. Pyrrolidine derivatives as plasmepsin inhibitors: Binding mode analysis assisted by molecular dynamics simulations of a highly flexible protein. ChemMedChem, 2010, 5 (3), 443-454.
56. Specker, E.; Bottcher, J.; Lilie, H.; Heine, A.; Schoop, A.; Muller, G.; Griebenow, N.; Klebe, G. An old target revisited: Two new privileged skeletons and an unexpected binding mode for hivprotease inhibitors. Angew Chem. Int. Ed. Engl., 2005, 44 (20), 3140-3144.
57. Hopkins, A. L.; Groom, C. R.; Alex, A. Ligand efficiency: A useful metric for lead selection. Drug Discov. Today, 2004, 9(10), 430-431.
58. Gamo, F.-J.; Sanz, L. M.; Vidal, J.; de Cozar, C.; Alvarez, E.; Lavandera, J.-L.; Vanderwall, D. E.; Green, D. V. S.; Kumar, V.; Hasan, S.; Brown, J. R.; Peishoff, C. E.; Cardon, L. R.; Garcia- Bustos, J. F. Thousands of chemical starting points for antimalarial lead identification. Nature, 2010, 465 (7296), 305-310.
59. Guller, R.; Binggeli, A.; Breu, V.; Bur, D.; Fischli, W.; Hirth, G.; Jenny, C.; Kansy, M.; Montavon, F.; Muller, M.; Oefner, C.; Stadler, H.; Vieira, E.; Wilhelm, M.; Wostl, W.; Marki, H. P. Piperidine-renin inhibitors compounds with improved physicochemical properties. Bioorg. Med. Chem. Lett., 1999, 9 (10), 1403-1408.
60. Vieira, E.; Binggeli, A.; Breu, V.; Bur, D.; Fischli, W.; Guller, R.; Hirth, G.; Marki, H. P.; Muller, M.; Oefner, C.; Scalone, M.; Stadler, H.; Wilhelm, M.; Wostl, W. Substituted piperidines-- highly potent renin inhibitors due to induced fit adaptation of the active site. Bioorg. Med. Chem.Lett., 1999, 9 (10), 1397-1402.
61. Oefner, C.; Binggeli, A.; Breu, V.; Bur, D.; Clozel, J. P.; D'Arcy, A.; Dorn, A.; Fischli, W.; Gruninger, F.; Guller, R.; Hirth, G.; Marki, H.; Mathews, S.; Mathews, M. L.; Ridley, R. G.; Stadler, H.; Vieira, E.; Wilhelm, M.; Winkler, F.; Wostl, W. Renin inhibition by substituted piperidines: A novel paradigm for the inhibition of monomeric aspartic proteinases? Chem. Biol., 1999, 6 (3), 127-131.
62. Boss, C.; Bur, D.; Corminboeuf, O.; Grisostomi, C.; Prade, L.; Weller, T. Novel 4-aminopiperidine derivatives. 2008. US Pat. App 11720181.
63. Boss, C.; Corminboeuf, O.; Grisostomi, C.; Meyer, S.; Jones, A. F.; Prade, L.; Binkert, C.; Fischli, W.; Weller, T.; Bur, D. Achiral, cheap, and potent inhibitors of plasmepsins i, ii, and iv. ChemMedChem, 2006, 1 (12), 1341-1345.
64. Prade, L.; Jones, A. F.; Boss, C.; Richard-Bildstein, S.; Meyer, S.; Binkert, C.; Bur, D. X-ray structure of plasmepsin ii complexed with a potent achiral inhibitor. J. Biol. Chem., 2005, 280 (25), 23837-23843.
65. Hof, F.; Schutz, A.; Fah, C.; Meyer, S.; Bur, D.; Liu, J.; Goldberg, D. E.; Diederich, F. Starving the malaria parasite: Inhibitors active against the aspartic proteases plasmepsins i, ii, and iv. Angew Chem. Int. Ed. Engl., 2006, 45 (13), 2138-2141.
66. Zurcher, M.; Hof, F.; Barandum, L.; Schutz, A.; Schweizer, W. B.; Meyer, S.; Bur, D.; Diederich, F. Synthesis of exo-3-amino-7- azabicyclo[2.2.1]heptanes as a class of malarial aspartic protease inhibitors: Exploration of tow binding pockets. Eur. J. Organic Chem., 2009, 2009(11), 1707-1719.
67. Moura, P. A.; Dame, J. B.; Fidock, D. A. Role of plasmodium falciparum digestive vacuole plasmepsins in the specificity and antimalarial mode of action of cysteine and aspartic protease inhibitors. Antimicrob. Agents Chemother., 2009, 53 (12), 4968-4978.
68. Andrews, K. T.; Fairlie, D. P.; Madala, P. K.; Ray, J.; Wyatt, D. M.; Hilton, P. M.; Melville, L. A.; Beattie, L.; Gardiner, D. L.; Reid, R. C.; Stoermer, M. J.; Skinner-Adams, T.; Berry, C.; McCarthy, J. S. Potencies of human immunodeficiency virus protease inhibitors in vitro against plasmodium falciparum and in vivo against murine malaria. Antimicrob. Agents Chemother., 2006, 50 (2), 639-648.
69. Guiguemde, W. A.; Shelat, A. A.; Bouck, D.; Duffy, S.; Crowther, G. J.; Davis, P. H.; Smithson, D. C.; Connelly, M.; Clark, J.; Zhu, F.; Jiménez-Díaz, M. B.; Martinez, M. S.; Wilson, E. B.; Tripathi, A. K.; Gut, J.; Sharlow, E. R.; Bathurst, I.; Mazouni, F. E.; Fowble, J. W.; Forquer, I.; McGinley, P. L.; Castro, S.; Angulo-Barturen, I.; Ferrer, S.; Rosenthal, P. J.; DeRisi, J. L.; Sullivan, D. J.; Lazo, J. S.; Roos, D. S.; Riscoe, M. K.; Phillips, M. A.; Rathod, P. K.; Van Voorhis, W. C.; Avery, V. M.; Guy, R. K. Chemical genetics of plasmodium falciparum. Nature, 2010, 465 (7296), 311-315.